STOCK TITAN

Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, at 1:20 p.m. ET. CEO Briggs W. Morrison will discuss the company's innovative cancer therapies pipeline, which includes SNDX-5613, axatilimab, and entinostat. A live webcast of the presentation can be accessed through the Investor section of Syndax's website, where a replay will also be available.

Loading...
Loading translation...

Positive

  • Syndax's pipeline includes promising cancer therapies like SNDX-5613, axatilimab, and entinostat.

Negative

  • None.
Argus Session date unavailable
-2.73% session move Open Argus
Details

News Market Reaction – SNDX

The recorded move for SNDX in the trading session of this news was -2.73%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will present at the Stifel 2020 Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 p.m. ET.

A live webcast of the presentation can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time. 

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. 

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Ted Held
ted.held@gcihealth.com
Tel 212.798.9842

SNDX-G

 

Cision View original content:http://www.prnewswire.com/news-releases/syndax-announces-presentation-at-stifel-2020-virtual-healthcare-conference-301170655.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What date will Syndax present at the Stifel 2020 Virtual Healthcare Conference?

Syndax will present on November 18, 2020.

Who is presenting Syndax's pipeline at the conference?

CEO Briggs W. Morrison will present at the conference.

What time is Syndax's presentation scheduled at the conference?

The presentation is scheduled for 1:20 p.m. ET.

Where can I watch Syndax's live presentation?

The live presentation can be accessed from the Investor section of Syndax's website.

What are the key therapies in Syndax's pipeline?

The key therapies include SNDX-5613, axatilimab, and entinostat.

Keep reading